LONDON: A new study finds that a monoclonal antibody approved by the Food and Drug Administration (FDA) is effective in protecting infants from catching Respiratory Syncytial Virus (RSV) disease that kills hundreds of babies each year.
According to British researchers those babies who received Beyfortus were less likely to require hospitalization due to a severe infection from RSV.
Overall, results revealed that the shot was 90 percent effective at preventing hospitalization in babies and almost 76 percent effective at preventing RSV associated infections.
Beyfortus, uses nirsevimab as the active ingredient and is developed and manufactured by the pair of European pharma companies AstraZeneca and Sanofi.
The Centers for Disease Control and Prevention recommended the shot for infants 19 months and younger after it was approved by the FDA in July.
Nirsevimab prepares children to fight RSV infection
Though nirsevimab is a shot, it is not considered as a vaccine in the typical sense. It is a monoclonal antibody treatment that prepare their bodies to fight an RSV infection.
Most people who catch RSV will not develop a serious illness. But for certain groups of people especially infants and older adults the virus can cause severe infection.
According to the CDC estimates there are more than 2 million outpatient visits hospitals especially children younger than five because of the RSV.
Up to 80,000 children per year are being hospitalized due to the virus which is responsible for up to 300 pediatric annual deaths.
In October, the CDC issued an advisory saying that the shot would be available in short supply throughout the 2023-2024 season.